Published in Cell on January 08, 2010
Clonal evolution in cancer. Nature (2012) 11.07
Interactions between cancer stem cells and their niche govern metastatic colonization. Nature (2011) 6.94
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell (2013) 2.68
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 2.22
Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2016) 2.11
Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene (2010) 1.92
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell (2010) 1.81
Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell (2014) 1.70
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 1.66
A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell (2012) 1.65
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol (2010) 1.63
Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev (2012) 1.61
In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol (2011) 1.61
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut (2015) 1.60
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. Cell Rep (2014) 1.58
SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer (2010) 1.56
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med (2013) 1.53
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain (2011) 1.48
Reactive oxygen species in cancer stem cells. Antioxid Redox Signal (2012) 1.44
The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science (2016) 1.44
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland. Cell Stem Cell (2016) 1.38
An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36
Reciprocal repression between P53 and TCTP. Nat Med (2011) 1.35
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med (2013) 1.33
Stem cells in the human breast. Cold Spring Harb Perspect Biol (2010) 1.33
Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol (2010) 1.31
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med (2014) 1.30
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res (2011) 1.29
Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab (2012) 1.28
TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun (2012) 1.23
p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A (2015) 1.20
Evolutionary determinants of cancer. Cancer Discov (2015) 1.19
Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res (2014) 1.19
The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res (2011) 1.18
A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci U S A (2015) 1.17
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res (2011) 1.12
Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J (2015) 1.11
MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest (2014) 1.07
Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis (2011) 1.05
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. EMBO Mol Med (2013) 1.04
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.04
Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol (2010) 1.03
Slow-cycling therapy-resistant cancer cells. Stem Cells Dev (2011) 1.03
NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res (2012) 1.02
Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ (2014) 1.02
New insights into prostate cancer stem cells. Cell Cycle (2013) 1.02
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res (2013) 1.00
HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget (2014) 1.00
SOX4 mediates TGF-β-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One (2013) 1.00
Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ (2012) 0.99
Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4. Cell Rep (2014) 0.98
Perspectives on cancer stem cells in osteosarcoma. Cancer Lett (2012) 0.97
Adult thymus contains FoxN1(-) epithelial stem cells that are bipotent for medullary and cortical thymic epithelial lineages. Immunity (2014) 0.97
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. Breast Cancer Res (2014) 0.97
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer (2015) 0.97
Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A (2015) 0.96
Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer (2010) 0.96
Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma. Mol Cell Proteomics (2013) 0.95
Breast cancer stem cells. Front Physiol (2013) 0.95
Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma. Neoplasia (2013) 0.95
Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg (2012) 0.94
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med (2013) 0.94
Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells. Stem Cell Reports (2014) 0.94
Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS One (2012) 0.93
Positional variations in mammary gland development and cancer. J Mammary Gland Biol Neoplasia (2013) 0.93
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
New Findings on Breast Cancer Stem Cells: A Review. J Breast Cancer (2015) 0.92
In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS One (2013) 0.92
Cancer stem cells: repair gone awry? J Oncol (2010) 0.92
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Stem cells from trabecular meshwork home to TM tissue in vivo. Invest Ophthalmol Vis Sci (2013) 0.92
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med (2003) 11.93
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell (2009) 6.64
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37
A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature (2002) 6.22
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol (2003) 5.43
Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A (2005) 5.37
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol (2005) 4.86
Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol (2006) 4.71
Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell (2008) 4.47
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell (2005) 4.36
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell (2008) 4.22
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol (2013) 4.21
Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol (2004) 4.04
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science (2007) 3.92
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol (2002) 3.67
Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol (2007) 3.62
Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg (2010) 3.61
Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci (2003) 3.37
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 3.37
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Breast cancer. Lancet (2005) 3.27
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell (2007) 3.16
The endocytic matrix. Nature (2010) 3.15
Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A (2009) 3.10
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol (2002) 3.10
Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin. Cell (2006) 3.06
Human chromosome 7: DNA sequence and biology. Science (2003) 3.02
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol (2009) 2.98
Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J (2004) 2.94
NUMB controls p53 tumour suppressor activity. Nature (2008) 2.91
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res (2006) 2.71
Molecular mechanisms of coupled monoubiquitination. Nat Cell Biol (2006) 2.69
HER2 testing in gastric cancer: a practical approach. Mod Pathol (2012) 2.68
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol (2004) 2.61
A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene (2002) 2.55
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr Biol (2007) 2.54
Endocytosis conducts the cell signaling orchestra. Cell (2006) 2.48
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res (2004) 2.46
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol (2007) 2.44
Eps8 controls actin-based motility by capping the barbed ends of actin filaments. Nat Cell Biol (2004) 2.40
Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature (2004) 2.39
Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol (2006) 2.36
Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast (2006) 2.36
Np95 is a histone-binding protein endowed with ubiquitin ligase activity. Mol Cell Biol (2004) 2.35
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst (2003) 2.25
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Regulation of actin dynamics by WASP and WAVE family proteins. Trends Cell Biol (2004) 2.19
Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat Cell Biol (2005) 2.16
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol (2008) 2.14
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat (2010) 2.14
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest (2003) 2.12
Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol (2005) 2.10
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07